Obalon Therapeutics Inc (OBLN) Stock Price, Quote, News and Overview
NASDAQ:OBLN - Nasdaq -
OBLN Quote, Performance and Key Statistics
3.05
-0.19 (-5.86%)
The current stock price of OBLN is 3.05 null. In the past month the price increased by 29.24%. In the past year, price increased by 296.1%.
OBLN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About OBLN
Company Profile
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company is headquartered in Carlsbad, California and currently employs 2 full-time employees. The company went IPO on 2016-10-06. The firm's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The firm has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Company Info
Obalon Therapeutics Inc
5421 Avenida Encinas Ste F
Carlsbad CALIFORNIA 92008 US
CEO: Andrew Rasdal
Employees: 2.0
Company Website: http://www.obalon.com/
Phone: 18584802400.0
Obalon Therapeutics Inc / OBLN FAQ
What is the stock price of Obalon Therapeutics Inc today?
The current stock price of OBLN is 3.05 null. The price decreased by -5.86% in the last trading session.
What is the ticker symbol for Obalon Therapeutics Inc stock?
The exchange symbol of Obalon Therapeutics Inc is OBLN and it is listed on the Nasdaq exchange.
On which exchange is OBLN stock listed?
OBLN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Obalon Therapeutics Inc stock?
0 analysts have analysed OBLN and the average price target is 18.82 null. This implies a price increase of 517.02% is expected in the next year compared to the current price of 3.05. Check the Obalon Therapeutics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Obalon Therapeutics Inc worth?
Obalon Therapeutics Inc (OBLN) has a market capitalization of 30.57M null. This makes OBLN a Nano Cap stock.
How many employees does Obalon Therapeutics Inc have?
Obalon Therapeutics Inc (OBLN) currently has 2.0 employees.
What are the support and resistance levels for Obalon Therapeutics Inc (OBLN) stock?
Obalon Therapeutics Inc (OBLN) has a support level at 3.04 and a resistance level at 3.43. Check the full technical report for a detailed analysis of OBLN support and resistance levels.
Is Obalon Therapeutics Inc (OBLN) expected to grow?
The Revenue of Obalon Therapeutics Inc (OBLN) is expected to grow by 953.33% in the next year. Check the estimates tab for more information on the OBLN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Obalon Therapeutics Inc (OBLN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OBLN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OBLN, evaluating the profitability, health, valuation and growth aspects
- Obalon Therapeutics Inc (OBLN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Obalon Therapeutics Inc (OBLN) Sales and EPS estimates to see what analysts future expectations are.
- Obalon Therapeutics Inc (OBLN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Obalon Therapeutics Inc (OBLN) Insider and Institutional Ownership to learn about the owners and their transactions.
- Obalon Therapeutics Inc (OBLN) Stock Chart to make your own analysis
- Obalon Therapeutics Inc (OBLN) Latest news and press-releases to stay up to date.
Does Obalon Therapeutics Inc (OBLN) stock pay dividends?
OBLN does not pay a dividend.
When does Obalon Therapeutics Inc (OBLN) report earnings?
Obalon Therapeutics Inc (OBLN) will report earnings on 2022-03-11, after the market close.
What is the Price/Earnings (PE) ratio of Obalon Therapeutics Inc (OBLN)?
Obalon Therapeutics Inc (OBLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).
OBLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OBLN. When comparing the yearly performance of all stocks, OBLN is one of the better performing stocks in the market, outperforming 95.43% of all stocks.
OBLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OBLN. Both the profitability and financial health of OBLN have multiple concerns.
OBLN Financial Highlights
Over the last trailing twelve months OBLN reported a non-GAAP Earnings per Share(EPS) of -3.17. The EPS increased by 76.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1391.09% | ||
| ROA | -64.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
OBLN Ownership and Analysts
For the next year, analysts expect an EPS growth of 43.12% and a revenue growth 953.33% for OBLN